Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit decline wasn't the result of a negative clinical or regulatory event specific to the company.
Inovio's shares, by contrast, appear to have simply followed the broader biotech industry lower last month, evinced by the poor performance of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) in October.
Source: Fool.com
